Regeneron and Sanofi’s PD-1 inhibitor Libtayo will be tested in tandem with a cancer vaccine developed by BioNTech in melanoma in people who have failed treatment with other checkpoint inhibitors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback